Adverse Events for Monoclonal Antibodies in Patients with Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
(1) Background: Allergic rhinitis (AR) is a common disease in otolaryngology and novel biological therapies are required for clinical needs. To assess the tolerability of monoclonal antibodies, justifying their clinical applications, we presented a comprehensive safety profile of biologics in AR; (2...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/8/2848 |
| _version_ | 1797604924054306816 |
|---|---|
| author | Yuxi Lin Weiqing Wang Zhenzhen Zhu Surita Aodeng Lei Wang Yuzhuo Liu Jingjing Li Yang Zha Xiaowei Wang Wei Lv |
| author_facet | Yuxi Lin Weiqing Wang Zhenzhen Zhu Surita Aodeng Lei Wang Yuzhuo Liu Jingjing Li Yang Zha Xiaowei Wang Wei Lv |
| author_sort | Yuxi Lin |
| collection | DOAJ |
| description | (1) Background: Allergic rhinitis (AR) is a common disease in otolaryngology and novel biological therapies are required for clinical needs. To assess the tolerability of monoclonal antibodies, justifying their clinical applications, we presented a comprehensive safety profile of biologics in AR; (2) Methods: A systematic literature search was conducted following PRISMA guidelines for randomized clinical trials comparing monoclonal antibodies and placebo in AR. PubMed, Web of Science, Medline, and Cochrane were searched up until 9 January 2023. Among 3590 records in total, 12 studies with more than 2600 patients were included. Quality was assessed for all studies using Cochrane risk-of-bias tool for randomized trials, and subgrouped meta-analysis was performed; (3) Results: We accomplished an up-to-date literature overview and analysis on adverse events of monoclonal antibodies in AR. Total, common, severe, discontinuation-causing, and serious adverse events failed to reach statistical significance. Country was an essential factor for heterogeneity, and urticaria was the adverse event at highest risk (RR 2.81, 95% CI 0.79–9.95); (4) Conclusions: Monoclonal antibodies are considered well tolerated and relatively safe in patients with AR. The regions of patients and hypersensitive adverse reactions such as urticaria require a special caution in biological treatments in AR. |
| first_indexed | 2024-03-11T04:53:44Z |
| format | Article |
| id | doaj.art-1c4756bdb3ba4768b7724381829c240e |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T04:53:44Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-1c4756bdb3ba4768b7724381829c240e2023-11-17T19:49:19ZengMDPI AGJournal of Clinical Medicine2077-03832023-04-01128284810.3390/jcm12082848Adverse Events for Monoclonal Antibodies in Patients with Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical TrialsYuxi Lin0Weiqing Wang1Zhenzhen Zhu2Surita Aodeng3Lei Wang4Yuzhuo Liu5Jingjing Li6Yang Zha7Xiaowei Wang8Wei Lv94+4 Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100006, ChinaDepartment of Otolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100006, ChinaDepartment of Otolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100006, ChinaDepartment of Otolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100006, ChinaDepartment of Otolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100006, ChinaDepartment of Otolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100006, ChinaDepartment of Otolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100006, ChinaDepartment of Otolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100006, ChinaDepartment of Otolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100006, ChinaDepartment of Otolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100006, China(1) Background: Allergic rhinitis (AR) is a common disease in otolaryngology and novel biological therapies are required for clinical needs. To assess the tolerability of monoclonal antibodies, justifying their clinical applications, we presented a comprehensive safety profile of biologics in AR; (2) Methods: A systematic literature search was conducted following PRISMA guidelines for randomized clinical trials comparing monoclonal antibodies and placebo in AR. PubMed, Web of Science, Medline, and Cochrane were searched up until 9 January 2023. Among 3590 records in total, 12 studies with more than 2600 patients were included. Quality was assessed for all studies using Cochrane risk-of-bias tool for randomized trials, and subgrouped meta-analysis was performed; (3) Results: We accomplished an up-to-date literature overview and analysis on adverse events of monoclonal antibodies in AR. Total, common, severe, discontinuation-causing, and serious adverse events failed to reach statistical significance. Country was an essential factor for heterogeneity, and urticaria was the adverse event at highest risk (RR 2.81, 95% CI 0.79–9.95); (4) Conclusions: Monoclonal antibodies are considered well tolerated and relatively safe in patients with AR. The regions of patients and hypersensitive adverse reactions such as urticaria require a special caution in biological treatments in AR.https://www.mdpi.com/2077-0383/12/8/2848allergic rhinitismonoclonal antibodiesbiologicsbiological therapiesadverse eventssafety |
| spellingShingle | Yuxi Lin Weiqing Wang Zhenzhen Zhu Surita Aodeng Lei Wang Yuzhuo Liu Jingjing Li Yang Zha Xiaowei Wang Wei Lv Adverse Events for Monoclonal Antibodies in Patients with Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials Journal of Clinical Medicine allergic rhinitis monoclonal antibodies biologics biological therapies adverse events safety |
| title | Adverse Events for Monoclonal Antibodies in Patients with Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
| title_full | Adverse Events for Monoclonal Antibodies in Patients with Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
| title_fullStr | Adverse Events for Monoclonal Antibodies in Patients with Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
| title_full_unstemmed | Adverse Events for Monoclonal Antibodies in Patients with Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
| title_short | Adverse Events for Monoclonal Antibodies in Patients with Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
| title_sort | adverse events for monoclonal antibodies in patients with allergic rhinitis a systematic review and meta analysis of randomized clinical trials |
| topic | allergic rhinitis monoclonal antibodies biologics biological therapies adverse events safety |
| url | https://www.mdpi.com/2077-0383/12/8/2848 |
| work_keys_str_mv | AT yuxilin adverseeventsformonoclonalantibodiesinpatientswithallergicrhinitisasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT weiqingwang adverseeventsformonoclonalantibodiesinpatientswithallergicrhinitisasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT zhenzhenzhu adverseeventsformonoclonalantibodiesinpatientswithallergicrhinitisasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT suritaaodeng adverseeventsformonoclonalantibodiesinpatientswithallergicrhinitisasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT leiwang adverseeventsformonoclonalantibodiesinpatientswithallergicrhinitisasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT yuzhuoliu adverseeventsformonoclonalantibodiesinpatientswithallergicrhinitisasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT jingjingli adverseeventsformonoclonalantibodiesinpatientswithallergicrhinitisasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT yangzha adverseeventsformonoclonalantibodiesinpatientswithallergicrhinitisasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT xiaoweiwang adverseeventsformonoclonalantibodiesinpatientswithallergicrhinitisasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT weilv adverseeventsformonoclonalantibodiesinpatientswithallergicrhinitisasystematicreviewandmetaanalysisofrandomizedclinicaltrials |